Historical Valuation
Cue Biopharma Inc (CUE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.33 is considered Undervalued compared with the five-year average of -3.48. The fair price of Cue Biopharma Inc (CUE) is between 1.68 to 2.29 according to relative valuation methord. Compared to the current price of 0.36 USD , Cue Biopharma Inc is Undervalued By 78.58%.
Relative Value
Fair Zone
1.68-2.29
Current Price：0.36
78.58%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cue Biopharma Inc (CUE) has a current Price-to-Book (P/B) ratio of 1.98. Compared to its 3-year average P/B ratio of 3.04 , the current P/B ratio is approximately -34.86% higher. Relative to its 5-year average P/B ratio of 3.40, the current P/B ratio is about -41.77% higher. Cue Biopharma Inc (CUE) has a Forward Free Cash Flow (FCF) yield of approximately -96.86%. Compared to its 3-year average FCF yield of -51.05%, the current FCF yield is approximately 89.74% lower. Relative to its 5-year average FCF yield of -38.93% , the current FCF yield is about 148.83% lower.
P/B
Median3y
3.04
Median5y
3.40
FCF Yield
Median3y
-51.05
Median5y
-38.93
Competitors Valuation Multiple
AI Analysis for CUE
The average P/S ratio for CUE competitors is 52.79, providing a benchmark for relative valuation. Cue Biopharma Inc Corp (CUE.O) exhibits a P/S ratio of 3.33, which is -93.7% above the industry average. Given its robust revenue growth of -35.58%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CUE
1Y
3Y
5Y
Market capitalization of CUE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CUE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CUE currently overvalued or undervalued?
Cue Biopharma Inc (CUE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.33 is considered Undervalued compared with the five-year average of -3.48. The fair price of Cue Biopharma Inc (CUE) is between 1.68 to 2.29 according to relative valuation methord. Compared to the current price of 0.36 USD , Cue Biopharma Inc is Undervalued By 78.58% .
What is Cue Biopharma Inc (CUE) fair value?
CUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cue Biopharma Inc (CUE) is between 1.68 to 2.29 according to relative valuation methord.
How does CUE's valuation metrics compare to the industry average?
The average P/S ratio for CUE's competitors is 52.79, providing a benchmark for relative valuation. Cue Biopharma Inc Corp (CUE) exhibits a P/S ratio of 3.33, which is -93.70% above the industry average. Given its robust revenue growth of -35.58%, this premium appears unsustainable.
What is the current P/B ratio for Cue Biopharma Inc (CUE) as of Jan 10 2026?
As of Jan 10 2026, Cue Biopharma Inc (CUE) has a P/B ratio of 1.98. This indicates that the market values CUE at 1.98 times its book value.
What is the current FCF Yield for Cue Biopharma Inc (CUE) as of Jan 10 2026?
As of Jan 10 2026, Cue Biopharma Inc (CUE) has a FCF Yield of -96.86%. This means that for every dollar of Cue Biopharma Inc’s market capitalization, the company generates -96.86 cents in free cash flow.
What is the current Forward P/E ratio for Cue Biopharma Inc (CUE) as of Jan 10 2026?
As of Jan 10 2026, Cue Biopharma Inc (CUE) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Cue Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cue Biopharma Inc (CUE) as of Jan 10 2026?
As of Jan 10 2026, Cue Biopharma Inc (CUE) has a Forward P/S ratio of 3.33. This means the market is valuing CUE at $3.33 for every dollar of expected revenue over the next 12 months.